This Article Full Text Full Text (PDF) All Versions of this Article: 109/10/1212    most recent 01.CIR.0000121326.69153.98v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lim, M. Articles by Krum, H. Search for Related Content PubMed PubMed Citation Articles by Lim, M. Articles by Krum, H. Related Collections Congestive Endothelium/vascular type/nitric oxide

(Circulation. 2004;109:1212-1214.)
© 2004 American Heart Association, Inc.

Brief Rapid Communications

Differential Effect of Urotensin II on Vascular Tone in Normal Subjects and Patients With Chronic Heart Failure

Melissa Lim, BBiomedSc; Suzy Honisett, BSc, PhD; Christopher D. Sparkes, BBiomedSc; Paul Komesaroff, MBBS, PhD, FRACP; Andrew Kompa, BSc, PhD; Henry Krum, MBBS, PhD, FRACP

From the National Health and Medical Research Council of Australia Centre of Clinical Research Excellence in Therapeutics (M.L., C.D.S., A.K., H.K.) and the Department of Medicine (S.H., P.K.), Monash University, Alfred Hospital, Melbourne, Victoria 3004, Australia.

Correspondence to Prof Henry Krum, NHMRC CCRE in Therapeutics, Department of Epidemiology and Preventive Medicine and Department of Medicine, Monash University, Alfred Hospital, Melbourne, Victoria 3004, Australia. E-mail henry.krum{at}med.monash.edu.au

Received October 23, 2003; de novo received November 27, 2003; revision received January 22, 2004; accepted January 27, 2004.

Background— Urotensin II (U-II) is a novel vasoactive peptide that also has direct hypertrophic and profibrotic effects on the myocardium. Upregulation of U-II and its receptor has been observed within the heart of patients with chronic heart failure (CHF). Furthermore, plasma levels of U-II have been found to be elevated in some but not all studies in such patients. However, the functional consequences of activation of the U-II system in patients with CHF, assessed by direct administration of exogenous U-II, have not been previously determined.

Methods and Results— We compared the effect of iontophoresed U-II on skin microvascular tone in normal subjects and patients with CHF, assessed with the use of laser Doppler velocimetry. U-II mediated a dose-dependent vasodilator response in normal subjects (baseline, 137.9±52; U-II, 10^-12 mol/L, 145±134; U-II, 10^-9 mol/L, 712±179; U-II, 10^-7 mol/L, 943±139 arbitrary flux units [AFUs], P<0.0001). In contrast, a dose-dependent vasoconstrictor response was observed in patients with CHF (baseline, 336.1±129; U-II, 10^-12 mol/L, 317±131; U-II, 10^-9 mol/L, 129±137; U-II, 10^-7 mol/L, 22.4±130 AFUs, P<0.05). Differences in flow between normal subjects and patients with CHF were significant overall (P<0.001, 2-way ANOVA) and at the U-II 10^-9 mol/L and U-II 10^-7 mol/L dose level by Student’s unpaired t test (P<0.05, P<0.0001, respectively). In contrast, there was no significant difference between baseline blood flux and any dose of U-II in either group (or between groups) when the opposite polarity was applied.

Conclusions— In addition to direct effects on the myocardium, U-II may contribute to the increased peripheral vascular tone that is characteristic of human CHF. The present observations support the contention that the U-II system may be a potentially important target for pharmacological blockade in the treatment of this condition.

Key Words: peptides • heart failure • vasculature • ions • endothelium

This article has been cited by other articles:

				A. D. Leonard, J. P. Thompson, E. L. Hutchinson, S. P. Young, J. McDonald, J. Swanevelder, and D. G. Lambert Urotensin II receptor expression in human right atrium and aorta: effects of ischaemic heart disease Br. J. Anaesth., April 1, 2009; 102(4): 477 - 484. [Abstract] [Full Text] [PDF]

				M. P. Quaile, H. Kubo, C. L. Kimbrough, S. A. Douglas, and K. B. Margulies Direct Inotropic Effects of Exogenous and Endogenous Urotensin-II: Divergent Actions in Failing and Nonfailing Human Myocardium Circ Heart Fail, January 1, 2009; 2(1): 39 - 46. [Abstract] [Full Text] [PDF]

				A. R. Pries, H. Habazettl, G. Ambrosio, P. R. Hansen, J. C. Kaski, V. Schachinger, H. Tillmanns, G. Vassalli, I. Tritto, M. Weis, et al. A review of methods for assessment of coronary microvascular disease in both clinical and experimental settings Cardiovasc Res, November 1, 2008; 80(2): 165 - 174. [Abstract] [Full Text] [PDF]

				A. E. S. Abdel-Razik, R. J. Balment, and N. Ashton Enhanced renal sensitivity of the spontaneously hypertensive rat to urotensin II Am J Physiol Renal Physiol, October 1, 2008; 295(4): F1239 - F1247. [Abstract] [Full Text] [PDF]

				J. P. Williams, J. P. Thompson, S. P. Young, S. J. Gold, J. McDonald, D. J. Rowbotham, and D. G. Lambert Nociceptin and urotensin-II concentrations in critically ill patients with sepsis Br. J. Anaesth., June 1, 2008; 100(6): 810 - 814. [Abstract] [Full Text] [PDF]

				D. G. Lambert Urotensin II: from osmoregulation in fish to cardiovascular regulation in man Br. J. Anaesth., May 1, 2007; 98(5): 557 - 559. [Full Text] [PDF]

				G. Giebing, M. Tolle, J. Jurgensen, J. Eichhorst, J. Furkert, M. Beyermann, F. Neuschafer-Rube, W. Rosenthal, W. Zidek, M. van der Giet, et al. Arrestin-Independent Internalization and Recycling of the Urotensin Receptor Contribute to Long-Lasting Urotensin II-Mediated Vasoconstriction Circ. Res., September 30, 2005; 97(7): 707 - 715. [Abstract] [Full Text] [PDF]